Childhood obesity linked to antibiotics, antacids


Thursday, 15 November, 2018

Childhood obesity linked to antibiotics, antacids

Avoiding giving young children antacids or antibiotics unless genuinely necessary will reduce their risk of becoming obese.

A new study has found that children who are given antibiotics or antacids in their first two years of life are more likely to become obese during their childhood.

The study, conducted by the Uniformed Services University of the Health Sciences (USU) in collaboration with Walter Reed National Military Medical Center, sought to identify modifiable risk factors that could help combat the obesity epidemic in the USA.

Based on previous studies, the researchers knew several commonly prescribed paediatric medications, like antibiotics and acid suppressants, can alter the development of the human microbiome, an internal ecosystem made up of bacteria that benefits the immune system. In addition to the adverse health effects of paediatric obesity, it also has a growing impact on military readiness — 80% of potential military recruits in the US are now rejected for enlistment, with obesity cited as the number one reason.

The researchers analysed healthcare records for 333,353 children in the Military Health System who were born between October 2006 and September 2013. About 241,500 of those children (72.4%) had been prescribed an antibiotic and just more than 39,400 (11.8%) were prescribed an acid suppressant before age two. They followed infants from the time they were initially exposed to these medications for as long as eight years and found there was an association between antibiotic prescriptions and obesity. This association persisted regardless of which class of antibiotics was prescribed, and it strengthened with each additional class of antibiotic that was prescribed. Antacids — including those used to control excess stomach acid as well as acid reflux — were also associated with obesity, with a stronger association for each 30-day supply prescribed. The link to obesity also grew commensurately with exposure to each additional medication group prescribed.

The interaction between gut bacteria, obesity and these medications is complex, and the association could be influenced by several other factors, such as diet, lead author Dr Cade Nylund, an associate professor of paediatrics at USU, said. However, the researchers believe these medications could increase gastric pH, which disrupts the native gastrointestinal microecosystem — how the body naturally digests and absorbs nutrients — and this may have an influence on weight gain.

Dr Nyland explained that while parents should not avoid antibiotics or acid medications when necessary, fevers in infants are often viral, and not treated effectively with antibiotics. Infants spitting up is also normal and, in most circumstances, they do not need acid-suppressing medications, he added. Most infants grow out of acid reflux by 12–18 months old.  When infant reflux is a concern, it could often be addressed by changing the mother’s diet when breastfeeding, by switching formula type or, if the baby is growing well and isn’t in discomfort, simply waiting to grow out of it.

“The role of the paediatrician in addressing the obesity epidemic is critical, and prevention is key,” Dr Nylund said. He hopes these findings will stimulate a critical review of unnecessary prescriptions in infants, ultimately making an impact on the obesity epidemic.

The study, ‘Antibiotic and Acid Suppression Medications during Early Childhood are Associated with Obesity’, has been published in British Medical Journal, Gut.

Image credit: ©stock.adobe.com/au/dementevajulia

Related News

Hong Kong to host Asia Summit on Global Health this May

The event will be held at the Hong Kong Convention and Exhibition Centre (HKCEC) from 16-17 May...

At-home care recipients in hospital longer compared to aged care residents

The study involved collaboration between the Southern Adelaide Local Health Network, Flinders...

SA physician selected for global health leadership program

Dr Chloe Furst, a dual-trained geriatrician and palliative care physician from the Central...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd